Comparison of the Transdermal Bisoprolol Patch with Oral Bisoprolol Fumarate Administration as a Therapeutic Agent for Idiopathic Frequent Premature Ventricular Contractions
-
- Shinohara Masaya
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Wada Ryou
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Yao Shintaro
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Yano Kensuke
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Akitsu Katsuya
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Koike Hideki
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Kinoshita Toshio
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Yuzawa Hitomi
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Suzuki Takeya
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Fujino Tadashi
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
-
- Ikeda Takanori
- Department of Cardiovascular Medicine, Toho University Faculty of Medicine
この論文をさがす
抄録
<p>The transdermal bisoprolol patch (TB) was designed to maintain a sustained concentration of bisoprolol in plasma by a higher trough concentration than oral bisoporolol (OB). We compared the efficacy between TB and OB in patients with idiopathic premature ventricular contractions (PVCs) while considering their duration of action.</p><p>A total of 78 patients with a PVC count of ≥ 3,000 beats/24 hours were divided into groups treated with TB 4 mg (n = 43) or OB 2.5 mg (n = 35). PVCs were divided into positive heart rate (HR) -dependent PVCs (P-PVCs) and non-positive HR-dependent PVCs (NP-PVCs) based on the relationship between the hourly PVC density and hourly mean HR. Twenty-four-hour Holter electrocardiograms were performed before and 1 to 3 months after the initiation of therapy.</p><p>There were no significant between-group differences in the baseline characteristics. Both the TB (from 14.6 [9.9-19.2] to 7.6 [1.7-15.8]%, P < 0.001) and OB (from 13.2 [7.6-21.9] to 4.6 [0.5-17.0]%, P = 0.0041) significantly decreased the PVC density, and there was no significant difference between the two groups (P = 0.73). Compared to OB, the TB had similar effects in reducing the PVC density for P-PVCs (P = 0.96), and NP-PVCs (P = 0.71). The TB significantly decreased the P-PVC density from baseline not only during day-time (P < 0.001) but also night-time (P = 0.0017), while the OB did not significantly decrease the P-PVC density from baseline during night-time (P = 0.17).</p><p>Compared to OB, the TB could be used with the same efficacy of reducing idiopathic PVCs. The TB may be a more useful therapeutic agent than OB for P-PVCs during a 24-hour period.</p>
収録刊行物
-
- International Heart Journal
-
International Heart Journal 61 (3), 510-516, 2020-05-30
一般社団法人 インターナショナル・ハート・ジャーナル刊行会